Conferences

CNS is one of the largest and fastest growing therapeutic areas of the pharmaceutical market. The ageing of the baby-boom generation combined with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer\'s disease and Parkinson\'s disease, will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic, and highly promising for pharmaceutical and biotechnology companies worldwide. (Source: Visiongain - World Neurodegenerative Diseases Market 2009 -2024)

At Visiongain’s CNS Clinical Trials conference you will examine the strategies offering the greatest potential for success in CNS drug development, and understand the specific challenges currently faced by developers in this market. In order to enhance productivity in this field, there has been an increased awareness of the need to align clinical and preclinical research to facilitate rapid development of new CNS drug therapies. Medical imaging is increasingly being used as a surrogate endpoint or biomarker of drug efficacy in all phases of CNS trials, enabling CNS developers to make more timely decisions.

As part of this 2-day event, leading industry and academic authorities will address how to balance risk and how attrition can be reduced to increase the chances of success in CNS clinical trials. Participants will look at overcoming some of the hurdles arising in designing, managing and recruiting for CNS clinical trials, and examine the tools and technologies to best enhance clinical development.

By attending this conference you will:

• Examine novel approaches for assessing cognitive function
• Explore the latest advances in neuroimaging
• Develop effective methods for improved patient recruitment and retention
• Understand statistical thinking for designing adaptive trials
• Review Good Clinical Practice GCP guidelines
• Address the regulatory challenges for CNS drug approval
• Utilise biomarkers for Proof of Concept in CNS clinical trials
• Improve trial outcomes through increased communication, ethical consent and patient care
• Implement translational methods to bridge the gap between pre-clinical and clinical CNS trials
• Be part of a major networking opportunity

Target Audience:

• Pharmaceutical and biotech companies
• Clinical research organisations
• Regulatory agencies/ associations

http://www.visiongain.com/Conference/257/CNS-Clinical-Trials